Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)

Authors

DOI:

https://doi.org/10.9771/cp.v13i3.36815

Keywords:

Technological Maturity Levels (TRL), Viruses, Pandemics, Therapies, Technology Assessment.

Abstract

This work analyzes the drugs used for patients with COVID-19 which are undergoing clinical trials and that go well beyond chloroquine. The data were obtained from the World Health Organization's International Clinical Trials Registration Platform. Geodistribution shows concentration in China, and only 5% of transnational partnerships. Clinical tests are concentrated in intermediate phases II and III. The classes of drugs go far beyond antimalarials, which have become popularly known, also comprising antivirals, anti-inflammatories, antibiotics, anticoagulants, antibodies, antifibrotics, antitumor agents, calcium channel blockers, corticosteroids, immunomodulators, immunosuppressants, enzyme inhibitors, mucolytics, vasoconstrictors and vasodilators, vitamins and mineral salts. The most tested antivirals are Ritonavir, Remdesivir, Lopinavir, Favipiravir and Arbidol, as well as their associations. Several tests combine antimalarials, antivirals and immunomodulators, the most studied being Favipiravir and Lopinavir associated with Ritonavir, Methylprednisolone, Remdesivir, Tocilizumab, Chloroquine and Hydroxychloroquine.

Downloads

Download data is not yet available.

Author Biographies

Cristina M. Quintella, Federal University of Bahia

  • ndereço para acessar este CV: http://lattes.cnpq.br/7897779819494573
  • ID Lattes: 7897779819494573

Lucilia Abreu Cabral e Silva, Federal University of Minas Gerais

Address to access this CV: http://lattes.cnpq.br/0347804913790816 Graduated in Medicine (2014 - 2020) at the Federal University of Minas Gerais, Brazil. She was part of the Research Project on Neuropsychiatric Diseases, under the guidance of Professor Aline Miranda, at the Interdisciplinary Laboratory for Medical Research (LIIM), Faculty of Medicine, UFMG (2016 - 2017). He worked in the Extension Project Adopt your neighborhood in times of coronavirus, from the Faculty of Medicine of UFMG, which promotes the performance of students of Nursing and Medicine courses in the fight against the new coronavirus (2020).

Heitor da Mata Quintella, Federal University of Minas Gerais

Address to access this CV: http://lattes.cnpq.br/6843746810740529 Graduated in Architecture and Urbanism from the Federal University of Bahia (2007-2011). Studying a degree in Medicine (2016 - Current) at the Federal University of Minas Gerais, Brazil

Gustavo Henrique Ramos Silva, Federal University of Minas Gerais

Address to access this CV: http://lattes.cnpq.br/3352093665267223 Studying a degree in Medicine (2016 - Current) at the Federal University of Minas Gerais, Brazil. He has developed research in Cellular Neuroelectrophysiology, is former Marketing Director of the Study Group in Applied Didactics to Medicine Students – GEDAAM and current member of the Scientific Committee of the Society of Medical Academics of Minas Gerais – SAMMG.

Sávio Carlos Rodrigues da Silva, Federal University of Minas Gerais

Address to access this CV: http://lattes.cnpq.br/9625804001105292 Studying a degree in Medicine (2016 - Current) at the Federal University of Minas Gerais, Brazil. She is part of the Research Group on Biology of the Lymphoid System and Regeneration, under the guidance of Professor Claudia Carvalho, at the Institute of Biological Sciences at UFMG (2017-current).

Sílvia Beatriz Beger Uchoa, Federal University of Alagoas

Address to access this CV: http://lattes.cnpq.br/2912504494560823 Graduated in Civil Engineering from the Federal University of Mato Grosso (1984); Master's degree in Architecture and Planning from the School of Engineering of São Carlos, University of São Paulo (1989) and PhD in Chemistry and Biotechnology - Physical-Chemistry Concentration Area, from the Institute of Chemistry and Biotechnology of UFAL (2007). She is currently a retired professor at the Federal University of Alagoas, having been Vice-coordinator of the PROFNIT Professional Master's - Focal Point UFAL until August 2018. She works as a professor in the PROFNIT/UFAL master's degree. She was coordinator of the Center for Technological Innovation and Special Programs at PROPEP/UFAL, coordinating the Institutional Program for Initiation Scholarships in Technological Development and Innovation - PIBITI from 2010 to January 2016. She has experience in the areas of Civil Construction and Electrochemistry, with emphasis on Construction Materials and Components and Corrosion and Durability Tests, working mainly on the following topics: civil construction, construction materials, concrete properties, durability of reinforced concrete structures and building facade pathologies. She was vice-coordinator of FORTEC Regional NE from April 2010 to April 2012 and alternate on the Fiscal Council of ANPROTEC.

Pedro Miguel de Assis Lopes Tavares da Mata, Hospital Garcia de Orta

Graduation in Medicine with specialization in Internal Medicine and Geriatrics (1992) at Hospital das Clínicas in São Paulo, Brazil. Specialization in Homeopathy (1995) at the São Paulo Homeopathy Association. Master in Palliative Care (2013) at Escola Superior de Saúde Prof. Lopes Dias in Portugal

References

BRISTOL MYERS SQUIBB. Opdivo® (nivolumabe) – Bula para o profissional de saúde. [2020]. Disponível em: https://consultas.anvisa.gov.br/#/medicamentos/25351308360201510/?nomeProduto=opdivo. Acesso em: 3 maio 2020.

CALY, Leon et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, [S.l.], v. 178, p. 104787-10, jun. 2020. Elsevier BV. DOI: http://dx.doi.org/10.1016/j.antiviral.2020.104787.

DOLHNIKOFF, Marisa et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. Journal Of Thrombosis And Haemostasis, [S.l.], p. 2-7, 15 abr. 2020. Wiley. DOI: http://dx.doi.org/10.1111/jth.14844.

DRUGBANK. Triazavirin. 2020. Disponível em: https://www.drugbank.ca/drugs/DB15622. Acesso em 3 maio 2020.

ESTADÃO. 2020. Disponível em: https://saude.estadao.com.br/noticias/geral,mandetta-afirma-que-pais-validou-e-esta-fornecendo-cloroquina-para-pacientes-mais-graves-de-covid-19,70003241781. Acesso em: 30 abr. 2020.

GAUTRET, Philippe et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, [S.l.], p. 105949, 2020.

GOOGLE TRENDS. 2020. Disponível em https://www.google.com/trends. Acesso em: 30 abr. 2020.

GREIN, Jonathan et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, Massachusetts Medical Society, p. 1-10, 10 abr. 2020. DOI: http://dx.doi.org/10.1056/nejmoa2007016.

HOFFMANN, Markus et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, [Elsevier BV], p. 1-10, mar. 2020. Disponível em: http://dx.doi.org/10.1016/j.cell.2020.02.052. Acesso em: 18 abr. 2020.

ICTRP – INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM. [2020]. Disponível em: https://www.who.int/ictrp/en/. Acesso em: 27 mar. 2020.

JANKUN, Jerzy. COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential therapeutics for SARS-CoV-2 coronavirus. UTJMS, [S.l.], v. 7, p 1-5, 2020. Disponível em: https://www.researchgate.net/publication/340949519_COVID-19_pandemic_transmembrane_protease_serine_2_TMPRSS2_inhibitors_as_potential_therapeutics_for_SARS-CoV-2_coronavirus_Coresponding_authors. Acesso em: 3 maio 2020.

LI, M. et al. Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-α, shows antitumor effect in vitro and in vivo. Cancer Cell International, [S.l.], v. 14, n.8, 2014. Disponível em: https://cancerci.biomedcentral.com/articles/10.1186/1475-2867-14-8. Acesso em: 3 maio 2020.

LONGA, L.; LEITE, L.; CARVALHO, M. Relatório Técnico IT/Gestec – Coronavírus. Vice-presidência de Produção e Inovação em Saúde, Fiocruz. 2020.

LOPES, Nei R.; ABREU, Maria Theresa C. L. Inibidores de tirosino quinase na leucemia mieloide crônica. Rev. Bras. Hematol. Hemoter., São Paulo, v. 31, n. 6, p. 449-453, 2009. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000600014&lng=en&nrm=iso. Acesso em:5 May 2020. (E-pub Dec 11, 2009)

LU, C. C.; CHEN, M. Y. J.; CHANGA, U. L. Potential therapeutic agents against COVID-19: What we know so far. Chin. Med. Assoc. [S.l.], v. 21 Apr. 2020. Disponivel em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176266/. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Azytromicin. 2020a. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/447043. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Arbidol. 2020b. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/131411. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Cobicistate. 2020c. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/25151504. Acesso em: 03/05/20.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Daclatasvir. 2020d. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/25154714. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Darunavir. 2020e. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/213039. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Favipiravir. 2020f. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/492405. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Ledipasvir. 2020g. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/67505836. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Oseltamivir. 2020h. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/65028. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Sofosbuvir. 2020i. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/45375808. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Ciclesonide. 2020j. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/6918155. Acesso em: 3 maio 2020

NIH. Drug Information Portal. 2020k. Disponível em: https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Baricitinibe. 2020l. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/44205240. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Rabeprazole. 2020m. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/5029. Acesso em: 3 maio 2020.

NIH. NTM-CBI. Pub Chem: Compound Sumary. Vitamin C. 2020n. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/54670067. Acesso em: 3 maio 2020.

QUINTELLA, C. M. et al. Maturidade Tecnológica: Níveis de Prontidão TRL. In: MOURA RIBEIRO, Núbia. (org.). PROFNIT, Prospecção Tecnológica. 1. ed. Salvador, BA: Editora do IFBA, 2019. v. 2, p. 18-59. Disponível em: http://www.profnit.org.br/pt/livros-profnit/. Acesso em: 2 abr. 2020.

QUINTELLA, C. M. et al. Vacinas para Coronavírus (COVID-19; SARS-COV-2): mapeamento preliminar de artigos, patentes, testes clínicos e mercado. Cadernos de Prospecção, Salvador, v. 13, p. 3-12, 2020a. DOI: 10.9771/cp.v13i1.35871.

QUINTELLA, C. M. et al. Coronavírus (SARS-COV-2) e COVID-19: mapeamento de testes clínicos. Cadernos de Prospecção, Salvador, v. 13, p. 397-411, 2020b. Disponível em https://portalseer.ufba.br/index.php/nit/article/view/36175. Acesso em: 10 maio 2020.

WANG, Manli et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, [S.l.], v. 30, n. 3, p. 269-271, 2020.

WHO – WORLD HEALTH ORGANIZATION. Situation reports. 2019. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavírus-2019/situation-reports/ Accesso em: 22 feb. 2020.

WHO – WORLD HEALTH ORGANIZATION. Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade. Autores: Estudo trilateral da Organização Mundial da Saúde (OMS), Organização Mundial da Propriedade Intelectual (OMPI) e Organização Mundial do Comércio (OMC). Data de publicação : 5 de fevereiro de 2013. Disponível em https://www.who.int/phi/promoting_access_medical_innovation/en/. Acesso em: 4 maio 2020.

XIAO-WEI, Xu et al. Clinical findings in a group of patients infected with the 2019 novel coronavírus (SARS-Cov-2) outside of Wuhan, China: retrospective case series BMJ, [S.l.], v. 368, m606, 2020.

YI, Y. et al. COVID-19: what has been learned and to be learned about the novel coronavírus disease. International Journal of Biological Sciences, [S.l.], v. 16, n. 10, p. 1.753, 2020.

ZHOU, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, (London, England), v. 395, n. 10229, p. 1.054-1.062, Mar 28, 2020.

ZHU, S. et al. Emerging Therapeutic Strategies for COVID-19 patients. Discoveries (Craiova), v. 8, n. 1, Jan-Mar., 2020.

Downloads

Published

2020-05-29

How to Cite

Quintella, C. M., Silva, L. A. C. e, Quintella, H. da M., Silva, G. H. R., Silva, S. C. R. da, Uchoa, S. B. B., & Mata, P. M. de A. L. T. da. (2020). Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus). Cadernos De Prospecção, 13(3), 599. https://doi.org/10.9771/cp.v13i3.36815

Issue

Vol. 13 No. 3 (2020)

Section

Coronavirus (SARS-COV-2) e COVID-19

License

Copyright (c) 2020 Cadernos de Prospecção

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos. Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.